MedTrace Logo

Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases

NCT07523282 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-04-14

No results posted yet for this study

Summary

This is an open-label, single-arm study designed to evaluate the safety and preliminary efficacy of HN2302 in patients with autoimmune diseases, including systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).

Conditions

Interventions

DRUG

HN2302 Injection

Dosing will begin at a lower dose level and may be escalated to dose levels considered safe and potentially effective according to the study protocol.

Sponsors & Collaborators

  • The First Affiliated Hospital of University of Science and Technology of China

    collaborator OTHER

  • Shenzhen MagicRNA Biotechnology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Zhu Chen · The First Affiliated Hospital of University of Science and Technology of China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-28
Primary Completion
2027-12-31
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07523282 on ClinicalTrials.gov